End-to-End Cell Therapy Manufacturing

Download the End to End Cell Shuttle Manufacturing Case Study to learn how Cellares offers a path to automated, reproducible, and scalable cell therapy manufacturing.

Learn about Cellares' integrated cell therapy manufacturing:

• Capable of manufacturing 16 cell therapy batches in parallel, which equates to 800 batches per year per Cell Shuttle (7-day process) or 2,800 batches per year per Cell Shuttle (2-day process)
• Compact automation reduces the facility size and workforce required by 90%
• Closing and automating the process reduces process failure rates by 75%